Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria

Fidel P Zavala, James P. Tam, Michael R. Hollingdale, Allan H. Cochrane, Isabella Quakyi, Ruth S. Nussenzweig, Victor Nussenzweig

Research output: Contribution to journalArticle

Abstract

Protective immunity against malaria can be obtained by vaccination with irradiated sporozoites. The protective antigens known as circumsporozoite (CS) proteins, are polypeptides that cover the surface membrane of the parasite. The CS proteins contain species-specific immunodominant epitopes formed by tandem repeated sequences of amino acids. Here it is shown that the dominant epitope of Plasmodium falciparum is contained in the synthetic dodecapeptide Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro or (NANP)3. Monoclonal antibodies and most or all polyclonal human antibodies to the sporozoites react with (NANP)3, and polyclonal antibodies raised against the synthetic peptide (NANP)3 react with the surface of the parasite and neutralize its infectivity. Since (NANP)3 repeats are present in CS proteins of P. falciparum from many parts of the world, this epitope is a logical target for vaccine development.

Original languageEnglish (US)
Pages (from-to)1436-1440
Number of pages5
JournalScience
Volume228
Issue number4706
StatePublished - 1985
Externally publishedYes

Fingerprint

Synthetic Vaccines
Falciparum Malaria
Sporozoites
Plasmodium falciparum
Epitopes
Parasites
Immunodominant Epitopes
Peptides
Proteins
Antibodies
Malaria
Amino Acid Sequence
Immunity
Vaccination
Vaccines
Monoclonal Antibodies
Antigens
Membranes
(asparaginyl-alanyl-asparaginyl-proline)3

ASJC Scopus subject areas

  • General

Cite this

Zavala, F. P., Tam, J. P., Hollingdale, M. R., Cochrane, A. H., Quakyi, I., Nussenzweig, R. S., & Nussenzweig, V. (1985). Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science, 228(4706), 1436-1440.

Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. / Zavala, Fidel P; Tam, James P.; Hollingdale, Michael R.; Cochrane, Allan H.; Quakyi, Isabella; Nussenzweig, Ruth S.; Nussenzweig, Victor.

In: Science, Vol. 228, No. 4706, 1985, p. 1436-1440.

Research output: Contribution to journalArticle

Zavala, FP, Tam, JP, Hollingdale, MR, Cochrane, AH, Quakyi, I, Nussenzweig, RS & Nussenzweig, V 1985, 'Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria', Science, vol. 228, no. 4706, pp. 1436-1440.
Zavala FP, Tam JP, Hollingdale MR, Cochrane AH, Quakyi I, Nussenzweig RS et al. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science. 1985;228(4706):1436-1440.
Zavala, Fidel P ; Tam, James P. ; Hollingdale, Michael R. ; Cochrane, Allan H. ; Quakyi, Isabella ; Nussenzweig, Ruth S. ; Nussenzweig, Victor. / Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. In: Science. 1985 ; Vol. 228, No. 4706. pp. 1436-1440.
@article{c9b9cab27c25472eb9963766638b3b81,
title = "Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria",
abstract = "Protective immunity against malaria can be obtained by vaccination with irradiated sporozoites. The protective antigens known as circumsporozoite (CS) proteins, are polypeptides that cover the surface membrane of the parasite. The CS proteins contain species-specific immunodominant epitopes formed by tandem repeated sequences of amino acids. Here it is shown that the dominant epitope of Plasmodium falciparum is contained in the synthetic dodecapeptide Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro or (NANP)3. Monoclonal antibodies and most or all polyclonal human antibodies to the sporozoites react with (NANP)3, and polyclonal antibodies raised against the synthetic peptide (NANP)3 react with the surface of the parasite and neutralize its infectivity. Since (NANP)3 repeats are present in CS proteins of P. falciparum from many parts of the world, this epitope is a logical target for vaccine development.",
author = "Zavala, {Fidel P} and Tam, {James P.} and Hollingdale, {Michael R.} and Cochrane, {Allan H.} and Isabella Quakyi and Nussenzweig, {Ruth S.} and Victor Nussenzweig",
year = "1985",
language = "English (US)",
volume = "228",
pages = "1436--1440",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "4706",

}

TY - JOUR

T1 - Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria

AU - Zavala, Fidel P

AU - Tam, James P.

AU - Hollingdale, Michael R.

AU - Cochrane, Allan H.

AU - Quakyi, Isabella

AU - Nussenzweig, Ruth S.

AU - Nussenzweig, Victor

PY - 1985

Y1 - 1985

N2 - Protective immunity against malaria can be obtained by vaccination with irradiated sporozoites. The protective antigens known as circumsporozoite (CS) proteins, are polypeptides that cover the surface membrane of the parasite. The CS proteins contain species-specific immunodominant epitopes formed by tandem repeated sequences of amino acids. Here it is shown that the dominant epitope of Plasmodium falciparum is contained in the synthetic dodecapeptide Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro or (NANP)3. Monoclonal antibodies and most or all polyclonal human antibodies to the sporozoites react with (NANP)3, and polyclonal antibodies raised against the synthetic peptide (NANP)3 react with the surface of the parasite and neutralize its infectivity. Since (NANP)3 repeats are present in CS proteins of P. falciparum from many parts of the world, this epitope is a logical target for vaccine development.

AB - Protective immunity against malaria can be obtained by vaccination with irradiated sporozoites. The protective antigens known as circumsporozoite (CS) proteins, are polypeptides that cover the surface membrane of the parasite. The CS proteins contain species-specific immunodominant epitopes formed by tandem repeated sequences of amino acids. Here it is shown that the dominant epitope of Plasmodium falciparum is contained in the synthetic dodecapeptide Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro or (NANP)3. Monoclonal antibodies and most or all polyclonal human antibodies to the sporozoites react with (NANP)3, and polyclonal antibodies raised against the synthetic peptide (NANP)3 react with the surface of the parasite and neutralize its infectivity. Since (NANP)3 repeats are present in CS proteins of P. falciparum from many parts of the world, this epitope is a logical target for vaccine development.

UR - http://www.scopus.com/inward/record.url?scp=0021800242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021800242&partnerID=8YFLogxK

M3 - Article

C2 - 2409595

AN - SCOPUS:0021800242

VL - 228

SP - 1436

EP - 1440

JO - Science

JF - Science

SN - 0036-8075

IS - 4706

ER -